226396-30-1 Usage
General Description
4-(2-(1-pyrrolidinyl)ethoxy)phenylboron, also known as PBEP, is a boronic acid derivative that is used in the field of chemical and pharmaceutical research. It is a versatile reagent that can be used to form carbon-carbon, carbon-nitrogen, and carbon-oxygen bonds through various organic reactions. PBEP is commonly utilized in the synthesis of complex organic compounds, including pharmaceuticals, agrochemicals, and materials. Its unique structure and reactivity make it an important tool for chemists and researchers working to develop new chemical entities and functional materials. Additionally, PBEP has shown potential as a potential therapeutic agent in medical research, due to its ability to interact with specific biological targets. Overall, the versatile and valuable properties of 4-(2-(1-pyrrolidinyl)ethoxy)phenylboron make it an important chemical compound in the realm of chemical and pharmaceutical research.
Check Digit Verification of cas no
The CAS Registry Mumber 226396-30-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,6,3,9 and 6 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 226396-30:
(8*2)+(7*2)+(6*6)+(5*3)+(4*9)+(3*6)+(2*3)+(1*0)=141
141 % 10 = 1
So 226396-30-1 is a valid CAS Registry Number.
226396-30-1Relevant articles and documents
FURANOPYRIMIDINES
-
Page/Page column 52-53, (2010/02/15)
The present invention relates to furanopyrimidine compounds having the general Formula (I) and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula (I), methods of treating various diseases and conditions in a mammal, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma and thymoma, comprising administering to the mammal a therapeutically effective amount of a compound of Formula (I). The invention also relates to methods of manufacturing medicaments, which comprise one or more compounds of Formula (I).
